

# CD16 / Fc-gamma Receptor III Antibody - With BSA and Azide

Mouse Monoclonal Antibody [Clone CB16 ]  
Catalog # AH11204

## Product Information

---

Application	IF, FC
Primary Accession	<a href="#">P08637</a>
Other Accession	<a href="#">2214</a> , <a href="#">372679</a>
Reactivity	Human
Host	Mouse
Clonality	Monoclonal
Isotype	Mouse / IgG1, kappa
Clone Names	CB16
Calculated MW	29089

## Additional Information

---

Gene ID	2214
Other Names	Low affinity immunoglobulin gamma Fc region receptor III-A, CD16a antigen, Fc-gamma RIII-alpha, Fc-gamma RIII, Fc-gamma RIIIa, FcRIII, FcRIIIa, FcR-10, IgG Fc receptor III-2, CD16a, FCGR3A, CD16A, FCG3, FCGR3, IGFR3
Application Note	IF~~1:50~200 FC~~1:10~50
Storage	Store at 2 to 8°C.Antibody is stable for 24 months.
Precautions	CD16 / Fc-gamma Receptor III Antibody - With BSA and Azide is for research use only and not for use in diagnostic or therapeutic procedures.

## Protein Information

---

Name	FCGR3A {ECO:0000303 PubMed:23006327}
Function	Receptor for the invariant Fc fragment of immunoglobulin gamma (IgG). Optimally activated upon binding of clustered antigen-IgG complexes displayed on cell surfaces, triggers lysis of antibody-coated cells, a process known as antibody-dependent cellular cytotoxicity (ADCC). Does not bind free monomeric IgG, thus avoiding inappropriate effector cell activation in the absence of antigenic trigger (PubMed: <a href="#">11711607</a> , PubMed: <a href="#">21768335</a> , PubMed: <a href="#">22023369</a> , PubMed: <a href="#">24412922</a> , PubMed: <a href="#">25786175</a> , PubMed: <a href="#">25816339</a> , PubMed: <a href="#">28652325</a> , PubMed: <a href="#">8609432</a> , PubMed: <a href="#">9242542</a> ). Mediates IgG effector functions on natural killer (NK) cells. Binds antigen-IgG complexes generated upon infection and triggers NK cell-dependent cytokine production and degranulation to limit viral load and propagation. Involved in

the generation of memory- like adaptive NK cells capable to produce high amounts of IFNG and to efficiently eliminate virus-infected cells via ADCC (PubMed:[24412922](#), PubMed:[25786175](#)). Regulates NK cell survival and proliferation, in particular by preventing NK cell progenitor apoptosis (PubMed:[29967280](#), PubMed:[9916693](#)). Following the engagement of antigen-IgG complexes, triggers phosphorylation of immunoreceptor tyrosine-based activation motif (ITAM)-containing adapters with subsequent activation of phosphatidylinositol 3-kinase signaling and sustained elevation of intracellular calcium that ultimately drive NK cell activation. The ITAM-dependent signaling coupled to receptor phosphorylation by PKC mediates robust intracellular calcium flux that leads to production of pro-inflammatory cytokines, whereas in the absence of receptor phosphorylation it mainly activates phosphatidylinositol 3-kinase signaling leading to cell degranulation (PubMed:[1825220](#), PubMed:[23024279](#), PubMed:[2532305](#)). Costimulates NK cells and trigger lysis of target cells independently of IgG binding (PubMed:[10318937](#), PubMed:[23006327](#)). Mediates the antitumor activities of therapeutic antibodies. Upon ligation on monocytes triggers TNFA-dependent ADCC of IgG-coated tumor cells (PubMed:[27670158](#)). Mediates enhanced opsonisation and ADCC in response to afucosylated IgGs (PubMed:[34485821](#), PubMed:[28566370](#)).

<b>Cellular Location</b>	Cell membrane; Single-pass type I membrane protein. Secreted. Note=Also exists as a soluble receptor
<b>Tissue Location</b>	Expressed in natural killer cells (at protein level) (PubMed:2526846). Expressed in a subset of circulating monocytes (at protein level) (PubMed:27670158).

## Background

---

It recognizes CD16 (FcγRIII), the low-affinity receptor for IgG with an apparent molecular weight of 50-80 kDa. CD16 is represented by two similar genes, CD16A (FcγRIIIA), which exists as a hetero-oligomeric polypeptide-anchored form in macrophages and NK cells and CD16B (FcγRIIIB), which exist as a monomeric GPI-anchored form in neutrophils. Furthermore, there are two known polymorphisms of CD16B, NA-1 and NA-2. Individuals homozygous for NA-2 show a lower phagocytic capacity compared with NA-1. CD16 binds IgG in the form of immune complexes and shows preferential binding of IgG1 and IgG3 isotypes and minimal binding of IgG2 and IgG4. Upon IgG binding, both CD16 isoforms initiate signal transduction cascades that lead to a variety of responses including antibody-dependent cell-mediated cytotoxicity (ADCC), phagocytosis, degranulation and proliferation.

## References

---

Deaglio S, Zubiaur M, Gregorini A, Bottarel F, Ausiello CM, Dianzani U, Sancho J, Malavasi F. Human CD38 and CD16 are functionally dependent and physically associated in natural killer cells. *Blood*. 2002 Apr 1;99(7):2490-8. (FC) | Zilber MT, Gregory S, Mallone R, Deaglio S, Malavasi F, Charron D, Gelin C. CD38 expressed on human monocytes: a coaccessory molecule in the superantigen-induced proliferation. *Proc Natl Acad Sci U S A*. 2000 Mar 14;97(6):2840-5. (Cell Separation) | Wirthmueller U, Kurosaki T, Murakami MS, Ravetch JV. Signal transduction by Fc gamma RIII (CD16) is mediated through the gamma chain. *J Exp Med*. 1992 May 1;175(5):1381-90

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.